Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Moderna, Inc. (MRNA : NSDQ)
 
 • Company Description   
Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.

Number of Employees: 4,700

 
 • Price / Volume Information   
Yesterday's Closing Price: $140.33 Daily Weekly Monthly
20 Day Moving Average: 33,348,144 shares
Shares Outstanding: 399.24 (millions)
Market Capitalization: $56,024.77 (millions)
Beta: 1.10
52 Week High: $176.66
52 Week Low: $22.28
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 131.68% 133.33%
12 Week 153.30% 147.95%
Year To Date 375.86% 324.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
325 BINNEY STREET
-
CAMBRIDGE,MA 02142
USA		 ph: 617-714-6500
fax: -		 ir@modernatx.com http://www.modernatx.com
 
 • General Corporate Information   
Officers
Stephane Bancel - Chief Executive Officer
Noubar B. Afeyan - Chairman
James M. Mock - Chief Financial Officer
Sandra Horning - Director
Elizabeth Nabel - Director

Peer Information
Moderna, Inc. (CORR.)
Moderna, Inc. (RSPI)
Moderna, Inc. (CGXP)
Moderna, Inc. (BGEN)
Moderna, Inc. (GTBP)
Moderna, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 60770K107
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/26
Next Expected EPS Date: 11/05/26
Share - Related Items
Shares Outstanding: 399.24
Most Recent Split Date: (:1)
Beta: 1.10
Market Capitalization: $56,024.77 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-1.08 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-6.09 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: 21.66% Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 8.29
Price/Cash Flow: -
Price / Sales: 25.15
EPS Growth
vs. Year Ago Period: 7.51%
vs. Previous Quarter: -66.95%
Sales Growth
vs. Year Ago Period: 2.11%
vs. Previous Quarter: -62.72%
ROE
06/30/26 - -28.30
03/31/26 - -26.64
12/31/25 - -30.15
ROA
06/30/26 - -19.39
03/31/26 - -19.32
12/31/25 - -22.95
Current Ratio
06/30/26 - 2.29
03/31/26 - 2.41
12/31/25 - 3.29
Quick Ratio
06/30/26 - 2.18
03/31/26 - 2.35
12/31/25 - 3.22
Operating Margin
06/30/26 - -102.07
03/31/26 - -104.14
12/31/25 - -145.16
Net Margin
06/30/26 - -141.43
03/31/26 - -143.55
12/31/25 - -145.16
Pre-Tax Margin
06/30/26 - -138.55
03/31/26 - -141.03
12/31/25 - -142.39
Book Value
06/30/26 - 16.93
03/31/26 - 18.67
12/31/25 - 22.14
Inventory Turnover
06/30/26 - 7.50
03/31/26 - 7.96
12/31/25 - 4.07
Debt-to-Equity
06/30/26 - 0.09
03/31/26 - 0.08
12/31/25 - 0.07
Debt-to-Capital
06/30/26 - 8.11
03/31/26 - 7.53
12/31/25 - 6.59
 

Powered by Zacks Investment Research ©